Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 280 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RESTART Clear all
Completed Phase 2 Interventional Results available

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00089024
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 20, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

Economic Incentives and vDOT for Latent Tuberculosis Infection

NCT05022862
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 20, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

NCT01227434
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 20, 2026, 4:43 PM EDT
Not listed Phase 1 Interventional

Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma

NCT02345824
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Ribociclib
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 20, 2026, 4:43 PM EDT
Active, not recruiting Phase 2 Interventional

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

NCT03220646
View directory record Official record
Conditions
Brain Tumor
Interventions
abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring

NCT07204756
View directory record Official record
Conditions
Postpartum, Hypertension, Hypertensive Disorder of Pregnancy
Interventions
2-Week Home Monitoring, 6-Week Home Monitoring
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 20, 2026, 4:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

NCT00472082
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
efalizumab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer

NCT04594096
View directory record Official record
Conditions
Cancer
Interventions
Telehealth visits, Standard of Care
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 29 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma

NCT01146054
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG)
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Early Phase 1 Interventional

A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL

NCT02046694
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Allopurinol
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 30 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

NCT01257594
View directory record Official record
Conditions
Brain Cancer
Interventions
erlotinib, Cytoreductive Surgery
Drug · Procedure
Lead sponsor
Andrew B Lassman, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 20, 2026, 4:43 PM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

NCT00472966
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 20, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

NCT05236062
View directory record Official record
Conditions
Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Interventions
Exercise, Attention control
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 20, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional

DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia

NCT03265717
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
INVAC-1
Biological
Lead sponsor
Invectys
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Restricted Convalescence: Outcomes Following Urogynecologic Procedures

NCT02138487
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
liberal postoperative activity, Restricted postoperative activity
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Single-agent Cobimetinib for Adults With Histiocytic Disorders

NCT02649972
View directory record Official record
Conditions
Histiocytic Disorders
Interventions
Cobimetinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 20, 2026, 4:43 PM EDT
Not listed Not applicable Interventional

RAGE-Control: Teaching Emotional Self-regulation Through Videogame Play

NCT03270813
View directory record Official record
Conditions
Anger, Aggression
Interventions
Relaxation training plus RAGE-Control, Relaxation training plus Sham Videogame
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder

NCT00099983
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Risperidone, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Tuscaloosa, Alabama • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 20, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Early Elbow Motion Improve Patient Outcomes After Surgically Treated Elbow Fractures?

NCT05980312
View directory record Official record
Conditions
Elbow Fracture, Range of Motion, Immobilization
Interventions
Splint Immobilization, Early Motion
Other
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 20, 2026, 4:43 PM EDT
Withdrawn Phase 1 Interventional

Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

NCT03189186
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic Kidney Cancer
Interventions
Pembrolizumab Injection [Keytruda], Cryoablation, Nephrectomy
Drug · Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 20, 2026, 4:43 PM EDT
Active, not recruiting Phase 2 Interventional

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

NCT03817398
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
Procedure · Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 4:43 PM EDT
Terminated Not applicable Interventional Results available

Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation

NCT01650298
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Drug (Direct thrombin or Factor Xa inhibitor)
Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 20, 2026, 4:43 PM EDT
Active, not recruiting Not applicable Interventional

Subclinical Lymphedema Treatment Study

NCT03292198
View directory record Official record
Conditions
Breast Cancer-related Subclinical Lymphedema
Interventions
20-30 mmHg compression sleeve and gauntlet, Manual Lymphatic Drainage
Other
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 20, 2026, 4:43 PM EDT